STOCK TITAN

Jaguar Health (JAGX) Stock News, Nov-Dec 2023

JAGX NASDAQ

Jaguar Health, Inc. develops plant-derived prescription medicines for gastrointestinal disease states in people and animals. Its human-health news centers on crofelemer, including Mytesi for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and rare-disease intestinal failure programs tied to microvillus inclusion disease and short bowel syndrome through Napo Pharmaceuticals and Napo Therapeutics.

Company updates also cover animal-health products such as conditionally approved Canalevia-CA1 for chemotherapy-induced diarrhea in dogs and the Neonorm franchise for gut health in animals. Recurring corporate news includes Nasdaq listing-compliance matters, reverse stock splits, warrant exercises, stockholder meetings, proxy proposals, and other capital-structure actions.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.55%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.81%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.94%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.16%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.28%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.28%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.40%
Tags
conferences

FAQ

What is the current stock price of Jaguar Health (JAGX)?

Jaguar Health (JAGX) last closed at $0.3864.

What is the market cap of Jaguar Health (JAGX)?

The market cap of Jaguar Health (JAGX) is approximately $5.2M.